NCT07200193
A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion moved earlier from Dec 31, 2032 to Feb 2031 Show 7 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 8 words
- Enrollment closed, study ongoing
- Final enrollment: 9 participants (planned 66)
- Trial arms changed: 3 → 1
- Study sites: 4 to 3
- Secondary endpoints: 18 to 12
- Minor Study sites: 2 to 4v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 1, 2026 to Dec 22, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety and tolerability of CRMA-1001
Timeframe: 6 months
Secondary (9)
Long-term safety of CRMA-1001
Pharmacokinetics of CRMA-1001 components (Cmax)
Pharmacokinetics of CRMA-1001 components (Tmax)
Pharmacokinetics of CRMA-1001 components (terminal clearance rate)
Pharmacokinetics of CRMA-1001 components (Vd)
Show 4 moreShow less
To evaluate the immunogenicity of CRMA-1001
To evaluate the effect of CRMA-1001 on circulating HBV biomarkers (HBsAg)
To evaluate the effect of CRMA-1001 on circulating HBV biomarkers (anti-HBs)
To evaluate the effect of CRMA-1001 on circulating HBV biomarkers (HBV DNA)
Arms and interventions
Experimental: CRMA-1001Other
Single ascending dose arm
Genetic: CRMA-1001
Sites
3 sites in 3 countries
Hong Kong 1, New Zealand 1, United Kingdom 1